Arrowhead Pharmaceuticals

We are hosting a conference call and webcast today at 4:30 p.m. ET to discuss fiscal 2026 third quarter financial results and provide a corporate update. To learn more or participate in the conference call: https://bit.ly/4gbSU8P #WeAreArrowhead

We’ve acquired an FDA Rare Pediatric Disease Priority Review Voucher (PRV) to be used for an upcoming sNDA submission for patients with severe hypertriglyceridemia (sHTG) Read the full announcement: https://bit.ly/3TC7VrU

On #WorldRNADay, we're celebrating the potential of RNA interference (RNAi) to transform medicine. Targeting disease at its source starts with understanding what causes it. RNA interference (RNAi) silences specific genes and stops harmful proteins before they are made. At Arrowhead, our proprietary TRiM platform is designed to accelerate the discovery and development of targeted RNAi therapies for diseases with significant unmet needs. By targeting the genes that drive disease, we're working to advance innovative medicines across a range of therapeutic areas. Learn more about our science and innovation: https://lnkd.in/g44Dkpvz

Familial Chylomicronemia Syndrome (FCS) is an under-diagnosed, rare, serious condition that affects the way your body processes fat from food. It can be clinically diagnosed or confirmed through genetic testing. The impact of rare diseases like FCS is often overlooked, but meaningful progress on FCS depends on action from every corner of the healthcare ecosystem. Whether you are a person living with FCS, a caregiver, a healthcare professional, a policymaker, or interested in helping make a difference, there are concrete steps we can all take right now. Your experience matters. Your voice matters. And together, we can push for a future where people with FCS have better support, better resources and better care. Understand more about what it’s like living with FCS through our Spotlight on FCS paper: www.SpotlightOnFCS.com

Do your patients present with unexplained abdominal pain, recurrent acute pancreatitis, or symptoms like skin changes, vision disturbances or cognitive challenges? When these symptoms arise alongside severely elevated triglycerides, it may indicate Familial Chylomicronemia Syndrome (FCS). FCS, is an underdiagnosed, rare, serious condition that affects the way your body processes fat from food. It can present with a wide range of symptoms from life-threatening acute pancreatitis and severe abdominal pain, to eruptive xanthomas, lipemia retinalis, and cognitive and emotional effects like anxiety, depression and brain fog—that impact nearly every part of daily life. For clinicians, recognizing this symptom profile earlier can be the difference between timely diagnosis and years of preventable suffering. Many of these symptoms are routinely attributed to lifestyle factors or other conditions, contributing to diagnostic delays that put patients at serious risk. For a clinical overview of FCS symptomatology, a comprehensive look at the disease, its burden, and the case for earlier identification and targeted intervention, read our “Spotlight on FCS” paper: SpotlightOnFCS.com

Arrowhead Pharmaceuticals has completed enrollment in the Phase 3 YOSEMITE study in adolescent and adult patients with homozygous familial hypercholesterolemia (HoFH) Learn more here: https://bit.ly/4wqwOVO

Breaking News: We’re pleased to announce positive topline results, with our Phase 3 SHASTA-3 and SHASTA-4 studies achieving the primary endpoint and all secondary endpoints in patients living with severe hypertriglyceridemia (sHTG). Learn more: https://lnkd.in/g38NByt8

Arrowhead Pharmaceuticals will host a webcast and conference call to discuss fiscal 2026 third quarter earnings, recent progress, and upcoming milestones. Learn more in today’s press release: https://bit.ly/4ywRSvf

We want to take a moment to reflect on the scale of chronic illness in the U.S. and the urgent need for continued progress in diagnosis, treatment and care. As you look through this snapshot of chronic disease by the numbers, consider what these statistics mean for people living with rare genetic conditions like Familial Chylomicronemia Syndrome (FCS) and Homozygous Familial Hypercholesterolemia (HoFH). At Arrowhead Pharmaceuticals, we're working to develop targeted therapies for people living with rare lipid disorders like FCS and HoFH. Because behind every statistic is a person, a family and a community that deserves better. #RareDisease

Reminder: Part I of our 2026 Summer Series of R&D Webinars is TODAY! Tune in to learn more about our cardiometabolic pipeline from external experts and our management team. Register on our website: https://bit.ly/4eJ4NkF #RNAi #TRiM #Cardiometabolic